药物性肾损伤机制、危险因素与创新预测技术的研究进展

doi:10.3969/j.issn.1004-583X.2026.01.015

摘要/Abstract

摘要：

药物性肾损伤(drug-induced kidney injury, DIKI)作为临床中常见且严重的并发症,显著影响患者的治疗效果与生活质量,因而成为肾脏病学和临床药理学领域的重要研究方向。当前,DIKI的发病机制复杂多样,涵盖细胞毒性、免疫介导损伤及氧化应激等多个方面,同时患者个体差异、药物特性及合并用药等也影响疾病的发生、发展。尽管目前已有大量基础和临床研究,但DIKI的早期诊断和预防仍面临诸多挑战。生物标志物的发现、先进影像学技术的应用及人工智能辅助预测模型的兴起,为DIKI的早期识别和风险评估带来了新的机遇。本文系统综述了DIKI的发病机制、危险因素及创新预测技术的最新研究进展,旨在为临床实践提供理论依据和技术支持,促进个体化治疗策略的建立与实施,推动药物安全性管理水平的提升。

关键词: 肾功能不全, 发病机制, 风险因素, 预测技术, 人工智能

中图分类号:

R692.5

鲍书敏, 张国娟. 药物性肾损伤机制、危险因素与创新预测技术的研究进展[J]. 临床荟萃, 2026, 41(1): 84-90.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://www.lchc.cn/CN/10.3969/j.issn.1004-583X.2026.01.015

https://www.lchc.cn/CN/Y2026/V41/I1/84

参考文献 63

[1]	Thawkar B, Rizwani F, Jain K. Drug-induced acute kidney injury: Mechanisms, biomarkers, and therapeutic strategies[J]. Curr Drug Saf, 2025. doi: 10.2174/0115748863362596250627155607.
[2]	Huang YZ, Chen YM, Lin CC, et al. A nursing note-aware deep neural network for predicting mortality risk after hospital discharge[J]. Int J Nurs Stud, 2024, 156:104797. doi: 10.1016/j.ijnurstu.2024.104797.
[3]	Nimri R, Phillip M. Enhancing care in type 1 diabetes with artificial intelligence driven clinical decision support systems[J]. Horm Res Paediatr, 2025, 98(4):384-395. doi: 10.1159/000546713.
[4]	Saeed I, Hashmi MU, Khalid M, et al. The role of artificial intelligence in heart failure diagnostics, risk prediction, and therapeutic strategies: A comprehensive review[J]. Cureus, 2025, 17(7):e87130. doi: 10.7759/cureus.87130.
[5]	Nakai K, Umehara M, Minamida A, et al. Streptozotocin induces renal proximal tubular injury through p53 signaling activation[J]. Sci Rep, 2023, 13(1):8705. doi: 10.1038/s41598-023-35850-w.
[6]	Okamoto K, Saito Y, Narumi K, et al. Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo[J]. Eur J Pharmacol, 2020, 884:173339. doi: 10.1016/j.ejphar.2020.173339.
[7]	Huo X, Meng Q, Wang C, et al. Protective effect of cilastatin against diclofenac-induced nephrotoxicity through interaction with diclofenac acyl glucuronide via organic anion transporters[J]. Br J Pharmacol, 2020, 177(9):1933-1948. doi: 10.1111/bph.14957.
[8]	He Y, Peng E, Ba X, et al. Ros responsive cerium oxide biomimetic nanoparticles alleviates calcium oxalate crystals induced kidney injury via suppressing oxidative stress and m1 macrophage polarization[J]. Small, 2025, 21(3):e2405417. doi: 10.1002/smll.202405417.
[9]	Wang Y, Liu Z, Ma J, et al. Lycopene attenuates the inflammation and apoptosis in aristolochic acid nephropathy by targeting the Nrf2 antioxidant system[J]. Redox Biol, 2022, 57:102494. doi: 10.1016/j.redox.2022.102494.
[10]	Chen W, Zhang K, Cui H, et al. Baicalin-2-ethoxyethyl ester alleviates gentamicin-induced acute kidney injury via NF-κB signaling pathway[J]. Biomed Pharmacother, 2024, 172:116276. doi: 10.1016/j.biopha.2024.116276.
[11]	Pavitrakar VN, Mody R, Ravindran S. Protective effects of recombinant human golimumab and pentoxifylline in nephrotoxicity induced by cisplatin[J]. J Biochem Mol Toxicol, 2022, 36(4):e22990. doi: 10.1002/jbt.22990.
[12]	Hasan IH, Shaheen SY, Alhusaini AM, et al. Simvastatin mitigates diabetic nephropathy by upregulating farnesoid X receptor and Nrf2/HO-1 signaling and attenuating oxidative stress and inflammation in rats[J]. Life Sci, 2024, 340:122445. doi: 10.1016/j.lfs.2024.122445.
[13]	Padala SA, Medepalli VM, Mohammed A, et al. Hydralazine-induced dual antineutrophil cytoplasmic antibody positive vasculitis and nephritis[J]. Cureus, 2020, 12(6):e8911. doi: 10.7759/cureus.8911.
[14]	Laamech R, Terrec F, Emprou C, et al. Efficacy of plasmapheresis in nivolumab-associated anca glomerulonephritis: A case report and pathophysiology discussion[J]. Case Rep Nephrol Dial, 2021, 11(3):376-383. doi: 10.1159/000518304.
[15]	Chen A, Yin L, Lee K, et al. Similarities and differences between covid-19-associated nephropathy and hiv-associated nephropathy[J]. Kidney Dis (Basel), 2022, 8(1):1-12. doi: 10.1159/000520235.
[16]	Neumann K, Tiegs G. Immune regulation in renal inflammation[J]. Cell Tissue Res, 2021, 385(2):305-322. doi: 10.1007/s00441-020-03351-1.
[17]	Sung C, Hayase N, Yuen P, et al. Macrophage depletion protects against cisplatin-induced ototoxicity and nephrotoxicity[J]. Sci Adv, 2024, 10(30):eadk9878. doi: 10.1126/sciadv.adk9878.
[18]	Sung CYW, Hayase N, Yuen PST, et al. Macrophage depletion protects against cisplatin-induced ototoxicity and nephrotoxicity[J]. bioRxiv [Preprint], 2023:2023.11.16.567274. doi: 10.1101/2023.11.16.567274.
[19]	Gai Z, Gui T, Kullak-Ublick GA, et al. The role of mitochondria in drug-induced kidney injury[J]. Front Physiol, 2020, 11:1079. doi: 10.3389/fphys.2020.01079.
[20]	Ba X, Ye T, He Y, et al. Engineered macrophage membrane-coated nanoparticles attenuate calcium oxalate nephrocalcinosis-induced kidney injury by reducing oxidative stress and pyroptosis[J]. Acta Biomater, 2025, 195:479-495. doi: 10.1016/j.actbio.2025.02.021.
[21]	Radi ZA. Kidney transporters and drug-induced injury in drug development[J]. Toxicol Pathol, 2020, 48(6):721-724. doi: 10.1177/0192623320937012.
[22]	Kulkarni P. Prediction of drug-induced kidney injury in drug discovery[J]. Drug Metab Rev, 2021, 53(2):234-244. doi: 10.1080/03602532.2021.1922436.
[23]	Niitsu T, Hayashi T, Uchida J, et al. Drug-induced kidney injury caused by osimertinib: Report of a rare case[J]. Nephron, 2022, 146(1):58-63. doi: 10.1159/000518774.
[24]	Liu C, Yan S, Wang Y, et al. Drug-induced hospital-acquired acute kidney injury in China: A multicenter cross-sectional survey[J]. Kidney Dis (Basel), 2021, 7(2):143-155. doi: 10.1159/000510455.
[25]	Rey A, Gras-Champel V, Choukroun G, et al. Risk factors for and characteristics of community-and hospital-acquired drug-induced acute kidney injuries[J]. Fundam Clin Pharmacol, 2022, 36(4):750-761. doi: 10.1111/fcp.12758.
[26]	Li Y, Ren K. The mechanism of contrast-induced acute kidney injury and its association with diabetes mellitus[J]. Contrast Media Mol Imaging, 2020, 2020:3295176. doi: 10.1155/2020/3295176.
[27]	Infante B, Conserva F, Pontrelli P, et al. Recent advances in molecular mechanisms of acute kidney injury in patients with diabetes mellitus[J]. Front Endocrinol(Lausanne), 2022, 13:903970. doi: 10.3389/fendo.2022.903970.
[28]	Bhattarai S, Pradhan SR, Bhattarai S. Low-dose atorvastatin therapy induced rhabdomyolysis in a liver cirrhosis patient-a case report[J]. Ann Med Surg (Lond), 2023, 85(10):5232-5234. doi: 10.1097/MS9.0000000000001231.
[29]	Wu NL, Hingorani S. Outcomes of kidney injury including dialysis and kidney transplantation in pediatric oncology and hematopoietic cell transplant patients[J]. Pediatr Nephrol, 2021, 36(9):2675-2686. doi: 10.1007/s00467-020-04842-7.
[30]	Huang YS, Wu CY, Chang TT, et al. Drug-induced liver injury associated with severe cutaneous adverse drug reactions: A nationwide study in Taiwan[J]. Liver Int, 2021, 41(11):2671-2680. doi: 10.1111/liv.14990.
[31]	Miao J, Herrmann SM. Immune checkpoint inhibitors and their interaction with proton pump inhibitors-related interstitial nephritis[J]. Clin Kidney J, 2023, 16(11):1834-1844. doi: 10.1093/ckj/sfad109.
[32]	Hakroush S, Kopp SB, Tampe D, et al. Variable expression of programmed cell death protein 1-ligand 1 in kidneys independent of immune checkpoint inhibition[J]. Front Immunol, 2020, 11:624547. doi: 10.3389/fimmu.2020.624547.
[33]	Yalçınkaya R, Öz FN, Kaman A, et al. Factors associated with acyclovir nephrotoxicity in children: Data from 472 pediatric patients from the last 10 years[J]. Eur J Pediatr, 2021, 180(8):2521-2527. doi: 10.1007/s00431-021-04093-0.
[34]	Vakilian A, Mohammadi S, Shokri F, et al. The renin-angiotensin system involvement in cisplatin-induced nephrotoxicity: An overview of physiological and pathological mechanisms-a systematic review[J]. Int J Nephrol, 2024, 2024:1511216. doi: 10.1155/2024/1511216.
[35]	Javed A, Mahmood T, Tiwari R, et al. Navigating nephropathy and nephrotoxicity: Understanding pathophysiology unveiling clinical manifestations, and exploring treatment approaches[J]. J Basic Clin Physiol Pharmacol, 2025, 36(2-3):69-93. doi: 10.1515/jbcpp-2024-0220.
[36]	Xie D, Hu G, Chen C, et al. Loss of sphingosine kinase 2 protects against cisplatin-induced kidney injury[J]. Am J Physiol Renal Physiol, 2022, 323(3):F322-F334. doi: 10.1152/ajprenal.00229.2021.
[37]	Desai RJ, Kazarov CL, Wong A, et al. Kidney damage and stress biomarkers for early identification of drug-induced kidney injury: A systematic review[J]. Drug Saf, 2022, 45(8):839-852. doi: 10.1007/s40264-022-01202-2.
[38]	Wang X, Mu J, Ma K, et al. Challenges of serum creatinine level in GFR assessment and drug dosing decisions in kidney injury[J]. Adv Pharm Bull, 2024, 14(4):745-758. doi: 10.34172/apb.42345.
[39]	Chen L, Smith J, Mikl J, et al. A multiplatform approach for the discovery of novel drug-induced kidney injury biomarkers[J]. Chem Res Toxicol, 2017, 30(10):1823-1834. doi: 10.1021/acs.chemrestox.7b00159.
[40]	Adedeji AO, Sonee M, Chen Y, et al. Evaluation of novel urinary biomarkers in beagle dogs with amphotericin b-induced kidney injury[J]. Int J Toxicol, 2023, 42(2):146-155. doi: 10.1177/10915818221142542.
[41]	Gu YZ, Vlasakova K, Darbes J, et al. Urine kidney safety biomarkers improve understanding of indirect intra-renal injury potential in dogs with a drug-induced prerenal azotemia[J]. Toxicology, 2020, 439:152462. doi: 10.1016/j.tox.2020.152462.
[42]	Sandelius Å, Basak J, Hölttä M, et al. Urinary kidney biomarker panel detects preclinical antisense oligonucleotide-induced tubular toxicity[J]. Toxicol Pathol, 2020, 48(8):981-993. doi: 10.1177/0192623320964391.
[43]	Kohl K, Herzog E, Dickneite G, et al. Evaluation of urinary biomarkers for early detection of acute kidney injury in a rat nephropathy model[J]. J Pharmacol Toxicol Methods, 2020, 105:106901. doi: 10.1016/j.vascn.2020.106901.
[44]	Chorley BN, Ellinger-Ziegelbauer H, Tackett M, et al. Urinary mirna biomarkers of drug-induced kidney injury and their site specificity within the nephron[J]. Toxicol Sci, 2021, 180(1):1-16. doi: 10.1093/toxsci/kfaa181.
[45]	Saito M, Horie S, Yasuhara H, et al. Metabolomic profiling of urine-derived extracellular vesicles from rat model of drug-induced acute kidney injury[J]. Biochem Biophys Res Commun, 2021, 546:103-110. doi: 10.1016/j.bbrc.2021.01.082.
[46]	Vivekaa A, Nellore J, Sunkar S. Zebrafish metabolomics: A comprehensive approach to understanding health and disease[J]. Funct Integr Genomics, 2025, 25(1):110. doi: 10.1007/s10142-025-01621-1.
[47]	Wang B, Wang Y, Wang J, et al. Multiparametric magnetic resonance investigations on acute and long-term kidney injury[J]. J Magn Reson Imaging, 2024, 59(1):43-57. doi: 10.1002/jmri.28784.
[48]	Virgincar RS, Wong AK, Barck KH, et al. Diffusion tensor MRI is sensitive to fibrotic injury in a mouse model of oxalate-induced chronic kidney disease[J]. Am J Physiol Renal Physiol, 2024, 327(2):F235-F244. doi: 10.1152/ajprenal.00099.2024.
[49]	Li A, Luo X, Li L, et al. Activatable multiplexed 19f magnetic resonance imaging visualizes reactive oxygen and nitrogen species in drug-induced acute kidney injury[J]. Anal Chem, 2021, 93(49):16552-16561. doi: 10.1021/acs.analchem.1c03744.
[50]	Chen Q, Yu J, Rush BM, et al. Ultrasound super-resolution imaging provides a noninvasive assessment of renal microvasculature changes during mouse acute kidney injury[J]. Kidney Int, 2020, 98(2):355-365. doi: 10.1016/j.kint.2020.02.011.
[51]	Kwon TJ, Jang E, Lee DS, et al. Development of a noninvasive kim-1-based live-imaging technique in the context of a drug-induced kidney-injury mouse model[J]. ACS Appl Bio Mater, 2021, 4(2):1508-1514. doi: 10.1021/acsabm.0c01392.
[52]	Tenebro CP, Marcial N, Salcepuedes JJ, et al. Visualization of renal rotenone accumulation after oral administration and in situ detection of kidney injury biomarkers via MALDI mass spectrometry imaging[J]. Front Mol Biosci, 2024, 11:1366278. doi: 10.3389/fmolb.2024.1366278.
[53]	Zhang G, Reeves WB. Spatial metabolomics in acute kidney injury[J]. Semin Nephrol, 2024, 44(6):151580. doi: 10.1016/j.semnephrol.2025.151580.
[54]	Rao M, Nassiri V, Srivastava S, et al. Artificial intelligence and machine learning models for predicting drug-induced kidney injury in small molecules[J]. Pharmaceuticals (Basel), 2024, 17(11):1550. doi: 10.3390/ph17111550.
[55]	Zhu W, Barreto EF, Li J, et al. Drug-drug interaction and acute kidney injury development: A correlation-based network analysis[J]. PLoS One, 2023, 18(1):e0279928. doi: 10.1371/journal.pone.0279928.
[56]	Yu P, Duan Z, Liu S, et al. Drug-induced nephrotoxicity assessment in 3D cellular models[J]. Micromachines (Basel), 2021, 13(1):3. doi: 10.3390/mi13010003.
[57]	Li X, Wang P, Zhu Y, et al. Interpretable machine learning model for predicting acute kidney injury in critically ill patients[J]. BMC Med Inform Decis Mak, 2024, 24(1):148. doi: 10.1186/s12911-024-02537-9.
[58]	Nagy M, Onder AM, Rosen D, et al. Predicting pediatric cardiac surgery-associated acute kidney injury using machine learning[J]. Pediatr Nephrol, 2024, 39(4):1263-1270. doi: 10.1007/s00467-023-06197-1.
[59]	Dong JF, Xue Q, Chen T, et al. Machine learning approach to predict acute kidney injury after liver surgery[J]. World J Clin Cases, 2021, 9(36):11255-11264. doi: 10.12998/wjcc.v9.i36.11255.
[60]	Liu W, Ji K, Tang Q, et al. Development and validation of interpretable machine learning models for predicting AKI risk in patients treated with PD-1/PD-L1: A retrospective study[J]. BMC Med Inform Decis Mak, 2025, 25(1):295. doi: 10.1186/s12911-025-03142-0.
[61]	Chen M, Zhang D. Machine learning-based prediction of post-induction hypotension: Identifying risk factors and enhancing anesthesia management[J]. BMC Med Inform Decis Mak, 2025, 25(1):96. doi: 10.1186/s12911-025-02930-y.
[62]	Qu C, Gao L, Yu XQ, et al. Machine learning models of acute kidney injury prediction in acute pancreatitis patients[J]. Gastroenterol Res Pract, 2020, 2020:3431290. doi: 10.1155/2020/3431290.
[63]	Hamed RG, Stephens G, Little M, et al. Data mapping challenges in reproducibility of machine learning for acute kidney injury prediction[J]. Stud Health Technol Inform, 2025, 328:220-224. doi: 10.3233/SHTI250706.

药物性肾损伤机制、危险因素与创新预测技术的研究进展

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 63

相关文章 15

编辑推荐

Metrics

本文评价

[1]	艾尼卡尔江·艾合麦提, 帕哈提·吐逊江, 伊木然·苏比, 徐蕊, 罕迦尔别克·库锟, 王云玲. 基于多模态MRI的人工智能预测模型在缺血性脑卒中的研究进展[J]. 临床荟萃, 2026, 41(1): 68-72.
[2]	武媛媛, 孟舰. 代谢重编程在脓毒症相关急性肾损伤中的研究进展[J]. 临床荟萃, 2025, 40(8): 753-757.
[3]	李逍山, 尚攀峰. 肾结核的多模态融合诊断[J]. 临床荟萃, 2025, 40(8): 758-763.
[4]	何媛, 王俭. 特发性脊柱侧凸患者神经与结构影像相关改变的研究进展[J]. 临床荟萃, 2025, 40(7): 669-672.
[5]	刘佳, 杨丰宇, 郭梦雅, 吴卓威, 张瀚文, 王译萱, 陈春红, 张芳. 低剂量利伐沙班用于肾功能不全的高龄心房颤动患者的安全性和有效性[J]. 临床荟萃, 2025, 40(6): 509-512.
[6]	王思晗, 李向红, 李亮亮, 锡洪敏, 杨萍, 马丽丽, 尹向云. 新生儿RYR1相关肌病1例并文献复习[J]. 临床荟萃, 2025, 40(6): 541-546.
[7]	潘凌峰, 林芳芳, 杨川. 人工智能在前列腺癌超声诊断中的应用[J]. 临床荟萃, 2025, 40(6): 547-552.
[8]	刘静, 李海鑫, 赵银霞. 儿童Papillorenal综合征2例临床特征并文献复习[J]. 临床荟萃, 2025, 40(11): 1027-1030.
[9]	陈家男, 罗群, 蔡珂丹. 心血管-肾脏-代谢综合征的诊治新进展[J]. 临床荟萃, 2025, 40(10): 948-953.
[10]	蒲茜, 成刚, 道杰草, 齐梓兆, 窦乐乐, 赵军芳, 张文君, 郭彩霞, 王莹莹. 甘肃地区单中心慢性肾脏病患者便秘患病率及危险因素分析[J]. 临床荟萃, 2025, 40(1): 44-53.
[11]	陈岚, 李叶琼, 冶秀鹏. 费城染色体阴性骨髓增殖性肿瘤患者血栓形成影响因素[J]. 临床荟萃, 2024, 39(4): 370-375.
[12]	储丽清, 杨敏. 运动疗法在慢性肾脏病中的应用进展[J]. 临床荟萃, 2024, 39(2): 183-187.
[13]	王鹏, 余玲, 李果, 庞敏, 胥力川, 张全波. 自噬与结核病相关性的研究进展[J]. 临床荟萃, 2024, 39(10): 953-968.
[14]	赵欣, 柳云. 生成式人工智能赋能医学人文教育的伦理审视[J]. 临床荟萃, 2024, 39(1): 65-69.
[15]	左腾, 王俊祥. 血清阴性类风湿关节炎发病机制的研究进展[J]. 临床荟萃, 2023, 38(8): 753-756.